FSI

FSI is a profitable but no-growth specialty-chemical micro-cap whose headline numbers look alarming and whose underlying business looks merely tired. Revenue of $38.5M was flat (+0.7%) and has now stagnated near $38M for three straight years after peaking at $45.8M/$7.02M net income in FY2022 — the trend is sideways-to-down, not up. The eye-watering 113.5x P/E is misleading: net income cratered 74% to $787K largely on one-time items the MD&A spells out — impairment of the Lygos investment, a loss on write-down of property held for sale, plus higher professional fees and SG&A tied to the new Panama location and scaling new products. Operating income still came in at $4.60M (11.9% margin), so the core remains cash-generative; normalized against FY2024's $3.04M net income the multiple is closer to ~28x — full, but not absurd.

The balance sheet is the real attraction and the reason this isn't a sell. Liabilities/equity is just 0.49x, long-term debt was cut 38.9% to $4.04M with the current portion down 81.5%, equity stands at $38.9M (~$3.06/share book), and the company holds cash while paying a dividend ($1.27M) and historically buying back stock. Working capital of ~$22M and the $3.75M sale of the 317 Mendota building give ample liquidity. This is not a company at risk of distress.